title: NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
abstract: The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice rapidly changed after the introduction of effective molecularly targeted therapy (such as imatinib and sunitinib) for GIST. Because of these changes, NCCN organized a multidisciplinary panel composed of experts in the fields of medical oncology, molecular diagnostics, pathology, radiation oncology, and surgery to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST Task Force is composed of NCCN faculty and other key experts from the United States, Europe, and Australia. The Task Force met for the first time in October 2003 and again in December 2006 with the purpose of expanding on the existing NCCN guidelines for gastrointestinal sarcomas and identifying areas of future research to optimize our understanding and treatment of GIST.
authors.forename: George D
authors.initials: GD
authors.lastname: Demetri
authors.forename: Robert S
authors.initials: RS
authors.lastname: Benjamin
authors.forename: Charles D
authors.initials: CD
authors.lastname: Blanke
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
authors.forename: Paolo
authors.initials: P
authors.lastname: Casali
authors.forename: Haesun
authors.initials: H
authors.lastname: Choi
authors.forename: Christopher L
authors.initials: CL
authors.lastname: Corless
authors.forename: Maria
authors.initials: M
authors.lastname: Debiec-Rychter
authors.forename: Ronald P
authors.initials: RP
authors.lastname: DeMatteo
authors.forename: David S
authors.initials: DS
authors.lastname: Ettinger
authors.forename: George A
authors.initials: GA
authors.lastname: Fisher
authors.forename: Christopher D M
authors.initials: CD
authors.lastname: Fletcher
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gronchi
authors.forename: Peter
authors.initials: P
authors.lastname: Hohenberger
authors.forename: Miranda
authors.initials: M
authors.lastname: Hughes
authors.forename: Heikki
authors.initials: H
authors.lastname: Joensuu
authors.forename: Ian
authors.initials: I
authors.lastname: Judson
authors.forename: Axel
authors.initials: A
authors.lastname: Le Cesne
authors.forename: Robert G
authors.initials: RG
authors.lastname: Maki
authors.forename: Michael
authors.initials: M
authors.lastname: Morse
authors.forename: Alberto S
authors.initials: AS
authors.lastname: Pappo
authors.forename: Peter W T
authors.initials: PW
authors.lastname: Pisters
authors.forename: Chandrajit P
authors.initials: CP
authors.lastname: Raut
authors.forename: Peter
authors.initials: P
authors.lastname: Reichardt
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Tyler
authors.forename: Annick D
authors.initials: AD
authors.lastname: Van den Abbeele
authors.forename: Margaret
authors.initials: M
authors.lastname: von Mehren
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Wayne
authors.forename: John
authors.initials: J
authors.lastname: Zalcberg
mesh_terms: D026683:Advisory Committees; D001549:Benzamides; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D007211:Indoles / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed; D014481:United States / Q000453:epidemiology
chemical_list: D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D000077210:Sunitinib